Bypass cheaper option over four years than angioplasty
This article was originally published in Clinica
The long-term costs of coronary artery bypass grafting (CABG) are significantly lower than for coronary angioplasty (PTCA), despite the fact that initial CABG costs are higher, according to a Japanese study.
You may also be interested in...
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.